Physician profile
Christopher Illick
NPI 1609836998
$4,942.06
in general payments reported to CMS, 2019-2025
30 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $486 · 2021: $207 · 2022: $99.82 · 2023: $955 · 2024: $981 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Education: $43.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.25 |
| Education | $43.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $585.16 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $523.78 | 2019-2025 | |
| Braintree Laboratories, INC. | $315.87 | 2019-2023 | Sutab |
| Janssen Biotech, INC. | $255.47 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Ferring Pharmaceuticals INC. | $180.69 | 2019-2020 | |
| Ardelyx, INC. | $178.11 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.45 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Qol Medical, LLC | $158.46 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $128.42 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $111.35 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $107.17 | 2024-2025 | Zenpep |
| Pfizer INC. | $105.67 | 2023-2025 | |
| Genzyme Corporation | $98.01 | 2023-2024 | |
| Madrigal Pharmaceuticals | $88.59 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $68.43 | 2023 | |
| Allergan, INC. | $31.10 | 2019 | |
| Daiichi Sankyo INC. | $29.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $26.80 | 2019 | |
| Shire North American Group INC | $26.14 | 2019 | |
| Exact Sciences Corporation | $24.71 | 2024 | Cologuard Collection Kit |
| Ucb, INC. | $23.33 | 2019 | |
| Celgene Corporation | $22.90 | 2024 | Zeposia |
| Alfasigma USA, INC. | $22.28 | 2020 | |
| Olympus America INC. | $21.11 | 2025 | Disposable Biopsy Forceps |
| Lilly USA, LLC | $20.81 | 2025 | Omvoh |
| Lucid Diagnostics INC. | $18.14 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Celltrion USA INC. | $13.53 | 2024 | Zymfentra |
| Astrazeneca Pharmaceuticals Lp | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Illick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.